RxDoctor Payments Data

Beth Moreland, NP

Family · Scottsdale, AZNPI 1407274780

Payments from drug & device makers

$7,971in general payments, 2019–2025

Across 468 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$772
  • Novo Nordisk$688
  • Pfizer$664
  • Lilly USA, LLC$661
  • Amgen$501
  • plus $3K from 47 others

What the payments were for

  • Food & beverage$7,956100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,971 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$12,067
Medicare patients
108
Services billed
210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide136$178,654
JardianceEmpagliflozin103$110,105
JanuviaSitagliptin Phosphate39$45,730
EliquisApixaban36$42,671
MounjaroTirzepatide31$38,432
XareltoRivaroxaban29$30,304
TrulicityDulaglutide16$18,983
RybelsusSemaglutide11$14,639
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$11,213
TradjentaLinagliptin15$10,260
Tresiba Flextouch U-100Insulin Degludec15$9,828
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$9,728
Spiriva RespimatTiotropium Bromide13$9,572
Breo ElliptaFluticasone/Vilanterol18$7,381
Jentadueto XrLinagliptin/Metformin Hcl13$7,051

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$688$193,293147 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Jentadueto Xr$225$136,989144 claims
Lilly USA, LLCMounjaro, Trulicity$661$57,41547 claims
MerckJanuvia$130$45,73039 claims
PfizerEliquis$664$42,67136 claims
Johnson & JohnsonXarelto$82$30,30429 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$123$21,86746 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.

Other family in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →